Focus on lower risk of tardive dyskinesia with atypical antipsychotics

Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists
Henry A Nasrallah

Abstract

Tardive dyskinesia (TD) is one of the most serious iatrogenic neurological complications of the first-generation antipsychotics. Identifying the risk factors for TD is important to minimize the risk of this potentially irreversible movement disorder in susceptible populations. A Medline search was conducted for the literature on risk factors for TD with the first-generation antipsychotics, as well as the emerging literature of the lower risk of TD with the second-generation antipsychotics. Several demographic, phenomenological, comorbidities and treatment variables have been reported to be associated with higher risk of TD. On the other hand, significantly lower rates of TD have been reported with the second-generation atypical antipsychotics, even in high risk groups such as the elderly. The use of the second-generation antipsychotics as first-line treatment of psychosis appears to have lowered the overall prevalence of acute movement disorders as well as TD, and have led them to become the standard of care in part because of their safer extrapyramidal profiles.

References

Feb 1, 1992·Pharmacogenetics·M PatelW Kalow
Jan 1, 1992·Journal of Diabetes and Its Complications·J S Cameron
Nov 6, 1991·JAMA : the Journal of the American Medical Association·B L SaltzK Kahaner
Jan 1, 1992·Social Science & Medicine·R Littlewood
Sep 1, 1985·Archives of General Psychiatry·J T WegnerJ M Kane
Apr 1, 1986·The American Journal of Psychiatry·J J SramekG M Simpson
Apr 1, 1986·Archives of General Psychiatry·S MukherjeeS Shukla
Nov 1, 1986·The British Journal of Psychiatry : the Journal of Mental Science·J L Waddington, H A Youssef
Nov 1, 1987·The American Journal of Psychiatry·W T CarpenterT E Hanlon
Nov 1, 1988·The American Journal of Psychiatry·H A NasrallahG A Hamdan-Allan
Aug 1, 1988·Journal of Clinical Psychopharmacology·G GardosP Moore
Mar 1, 1985·The American Journal of Psychiatry·W G CampbellC M Shaw
Aug 1, 1974·Journal of Neurology, Neurosurgery, and Psychiatry·H L Klawans, R Rubovits
Jul 5, 1973·The New England Journal of Medicine
Jul 1, 1973·Journal of Autism and Childhood Schizophrenia·P PolizosJ Waizer
Jan 1, 1970·Acta Psychiatrica Scandinavica·E ChristensenA Faurbye
Aug 1, 1980·The American Journal of Psychiatry·H L KlawansS Perlik
Dec 1, 1980·Archives of General Psychiatry·J M Smith, R J Baldessarini
Apr 1, 1982·Archives of General Psychiatry·J M Kane, J M Smith
Feb 1, 1983·The American Journal of Psychiatry·G Gardos, J O Cole
Apr 1, 1983·The American Journal of Psychiatry·K M Lin, E Finder
Feb 1, 1983·Psychological Medicine·T R BarnesS M Gore
Jan 1, 1983·Clinical Neuropharmacology·M CampbellW G Bennett
Feb 1, 1984·Psychosomatics·R YassaG Schwartz
Sep 1, 1984·The British Journal of Psychiatry : the Journal of Mental Science·W GreilE Rüther
Aug 1, 1984·Neurology·P K MölsäU K Rinne
Sep 1, 1995·Archives of General Psychiatry·D V JesteL A McAdams
Jun 1, 1993·The American Journal of Psychiatry·M G WoernerJ M Alvir
Jun 1, 1996·Pharmacogenetics·A K DalyU M Zanger
Nov 13, 1998·The American Journal of Psychiatry·M G WoernerJ M Kane
Jun 30, 2000·The American Journal of Psychiatry·D V JesteR A Martinez
Oct 6, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J M Kane
Dec 31, 2002·Psychoneuroendocrinology·J H Friedman
Jun 20, 2003·Biological Psychiatry·Christian R Dolder, Dilip V Jeste
Jan 30, 2004·Diabetes Care·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity

❮ Previous
Next ❯

Citations

Aug 3, 2011·The Pharmacogenomics Journal·L GreenbaumB Lerer
Oct 25, 2007·Expert Opinion on Pharmacotherapy·Jonathan C PfeiferMelissa P DelBello
Apr 1, 2011·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Na-Ri Kang, Moon-Doo Kim
Jul 7, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Lefteris LykourasRossetos Gournellis
Apr 14, 2015·The Cochrane Database of Systematic Reviews·Adegoke Oloruntoba AdelufosiTunde Massey-Ferguson Ojo
Sep 8, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Maria Sierra PeñaJoseph Jankovic
Dec 7, 2006·European Archives of Psychiatry and Clinical Neuroscience·Jose de Leon
Oct 13, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Lior GreenbaumBernard Lerer
May 6, 2010·CNS Drugs·Jonathan C PfeiferMelissa P DelBello
Sep 2, 2016·Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Österreichischer Nervenärzte und Psychiater·W Wolfgang FleischhackerKlaus Seppi
Oct 9, 2007·Current Opinion in Psychiatry·Jessica Broadway, Jacobo Mintzer
Jan 29, 2008·Journal of Clinical Pharmacology·Christopher KenneyJoseph Jankovic
Jul 4, 2006·CNS Spectrums·Guy MaytalTheodore A Stern

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here